PAION Announces Patient Recruitment For Phase IIa Study With Its Short Acting Anesthetic/Sedative CNS 7056 Successfully Completed

The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today announces the successful completion of the Recruitment for the Phase IIa clinical trial assessing the new short-acting intravenous anesthetic/sedative CNS 7056 in patients undergoing endoscopy of the upper gastrointestinal tract. "Again our development team has beaten our expectations.